Circulating tumor cells: from new biological insights to clinical practice
X Gu, S Wei, X Lv - Signal Transduction and Targeted Therapy, 2024 - nature.com
The primary reason for high mortality rates among cancer patients is metastasis, where
tumor cells migrate through the bloodstream from the original site to other parts of the body …
tumor cells migrate through the bloodstream from the original site to other parts of the body …
Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC
A Das, DD Shapiro, JK Craig, EJ Abel - Nature Reviews Urology, 2023 - nature.com
Cytoreductive nephrectomy became accepted as standard of care for selected patients with
metastatic renal cell carcinoma (mRCC) because of improved survival observed in patients …
metastatic renal cell carcinoma (mRCC) because of improved survival observed in patients …
Dissecting order amidst chaos of programmed cell deaths: construction of a diagnostic model for KIRC using transcriptomic information in blood-derived exosomes …
C Wang, Y He, J Zheng, X Wang, S Chen - Frontiers in Immunology, 2023 - frontiersin.org
Background Kidney renal clear cell carcinoma (KIRC) is the most frequently diagnosed
subtype of renal cell carcinoma (RCC); however, the pathogenesis and diagnostic …
subtype of renal cell carcinoma (RCC); however, the pathogenesis and diagnostic …
Pembrolizumab in combination with LEnvatinib in participants with hepatocellular carcinoma before liver transplant as Neoadjuvant TherapY—PLENTY pilot study
Z Lv, X Xiang, J Yong, Y Zhou, Y Wu, L Li… - … Journal of Surgery, 2024 - journals.lww.com
Background: The high recurrent rate after liver transplantation (LT) remains a clinical
challenge, especially for those exceeding the Milan criteria (MC) and with high RETREAT …
challenge, especially for those exceeding the Milan criteria (MC) and with high RETREAT …
Diagnostic miRNA signatures in paired tumor, plasma, and urine specimens from renal cell carcinoma patients
MA Bustos, J Gottlieb, J Choe, R Suyeon… - Clinical …, 2024 - academic.oup.com
Background The incidence of patients diagnosed with renal cell carcinoma (RCC) is
increasing. There are no approved biofluid biomarkers for routine diagnosis of RCC …
increasing. There are no approved biofluid biomarkers for routine diagnosis of RCC …
ctDNA predicts clinical T1a to pathological T3a upstaging after partial nephrectomy
JS Park, H Kim, WS Jang, J Kim, WS Ham… - Cancer …, 2024 - Wiley Online Library
Most patients diagnosed with clear cell renal cell carcinoma (ccRCC) are also detected with
small and organ‐confined tumors, and the majority of these are classified as clinical tumor …
small and organ‐confined tumors, and the majority of these are classified as clinical tumor …
Comprehensive systematic review of biomarkers in metastatic renal cell carcinoma: Predictors, prognostics, and therapeutic monitoring
Simple Summary This comprehensive systematic review provides valuable insights into the
landscape of biomarkers in clear cell renal cell carcinoma (ccRCC) and their potential …
landscape of biomarkers in clear cell renal cell carcinoma (ccRCC) and their potential …
Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy
The approval of monoclonal antibodies against programmed death-ligand 1 (PD-L1) and
programmed cell death protein (PD1) has changed the landscape of cancer treatment. To …
programmed cell death protein (PD1) has changed the landscape of cancer treatment. To …
Changes of circulating tumor cells expressing CD90 and EpCAM in early-phase of atezolizumab and bevacizumab for hepatocellular carcinoma
T Nosaka, Y Murata, Y Akazawa, K Takahashi, T Naito… - Heliyon, 2024 - cell.com
Circulating tumor cells (CTCs) are noninvasive biomarkers that can indicate the therapeutic
response and prognosis. The study aimed to investigate the cellular characteristics of CTCs …
response and prognosis. The study aimed to investigate the cellular characteristics of CTCs …
Circulating tumor cells as a predictor and prognostic tool for metastatic clear cell renal carcinoma: An immunocytochemistry and genomic analysis
MS Tariki, CCG Barberan, JA Torres… - … -Research and Practice, 2024 - Elsevier
Background Treatment of metastatic clear cell renal carcinoma (mccRCC) has changed
dramatically over the past 20 years, without improvement in the development of biomarkers …
dramatically over the past 20 years, without improvement in the development of biomarkers …